XYD-8006 / Kunshan Xinyunda Biotech - LARVOL DELTA

XYD-8006: A novel ADAM9-targeting dual-payload ADC demonstrates superior preclinical efficacy in gastrointestinal and lung cancer models (AACR 2026) - "XYD-8006 was designed to overcome key limitations of current ADC therapies. Its promising preclinical efficacy across gastrointestinal and lung cancers supports its further development, with an expected entry into clinical study in 2026."

ADC • Preclinical • Gastrointestinal Cancer • Lung Cancer • Oncology • Solid Tumor • ADAM9